pharma · Urea cycle disorders (UCD) · Cannabis Smoking · CAMP
Camp4 Therapeutics
Camp4 Therapeutics Corp
Camp4 Therapeutics patent portfolio — 4 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2016
- Employees
- 60
- Programs
- 9
- Drugs
- 15
- Patents
- 4
Camp4 Therapeutics patents
4 pharmaceutical patents indexed for Camp4 Therapeutics. 0 expire within 24 months.
Camp4 Therapeutics has 4 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12319916
Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
granted -
US 12145963
Phenothiazine derivatives and uses thereof
granted -
US 11542290
Phenothiazine derivatives and uses thereof
granted -
US 11266655
Methods and compositions for treating urea cycle disorders
granted
Frequently asked questions
How many patents does Camp4 Therapeutics have?
4 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Camp4 Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.